Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis

Journal of Virology

Volumn 82, Issue 3, 2008, Pages 1448-1457

  Elliott, Suzanne L ^a   Suhrbier, Andreas ^a,b   Miles, John J ^a   Lawrence, Greg ^a   Pye, Stephanie J ^a   Le, Thuy T ^a   Rosenstengel, Andrew ^a   Nguyen, Tam ^a   Allworth, Anthony ^b   Burrows, Scott R ^a   Cox, John ^c   Pye, David ^c   Moss, Denis J ^a   Bharadwaj, Mandvi ^a,d  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c CSL LIMITED   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; EPITOPE; HLA B ANTIGEN; MONTANIDE ISA 720; PEPTIDE VACCINE; PHENYLALANYLLEUCYLARGINYLGLYCYLARGINYLALANYLTYROSYLGLYCYLLEUCINE; PLACEBO; TETANUS TOXOID; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GENE SEQUENCE; HUMAN; HUMAN EXPERIMENT; INFECTIOUS MONONUCLEOSIS; INJECTION SITE REACTION; MALE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SEROCONVERSION; SERODIAGNOSIS; SINGLE BLIND PROCEDURE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HERPESVIRUS 4, HUMAN; HERPESVIRUS VACCINES; HLA-B ANTIGENS; HUMANS; INFECTIOUS MONONUCLEOSIS; MANNITOL; OLEIC ACIDS; SINGLE-BLIND METHOD; TETANUS TOXOID; VACCINES, SUBUNIT;

HUMAN HERPESVIRUS 4;

EID: 38349095359     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01409-07     Document Type: Article

References (63)

1. Adams, L. A., B. Deboer, G. Jeffrey, R. Marley, and G. Garas. 2006. Ganciclovir and the treatment of Epstein-Barr virus hepatitis. J. Gastroenterol. Hepatol. 21:1758-1760.
2. Aichele, P., K. Brduscha-Riem, S. Oehen, B. Odermatt, R. M. Zinkernagel, H. Hengartner, and H. Pircher. 1997. Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity 6:519-529.
3. Argaet, V. P., C. W. Schmidt, S. R. Burrows, S. L. Silins, M. G. Kurilla, D. L. Doolan, A. Suhrbier, D. J. Moss, E. Kieff, T. B. Sculley, and I. S. Misko. 1994. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J. Exp. Med. 180:2335-2340.
4. Bharadwaj, M., S. R. Burrows, J. M. Burrows, D. J. Moss, M. Catalina, and R. Khanna. 2001. Longitudinal dynamics of antigen-specific CD8+ cytotoxic T lymphocytes following primary Epstein-Barr virus infection. Blood 98:2588-2589.
5. Bharadwaj, M., M. Sherritt, R. Khanna, and D. J. Moss. 2001. Contrasting Epstein-Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design. Vaccine 19:3769-3777.
6. Black, C. A. 1999. Delayed type hypersensitivity: current theories with an historic perspective. Dermatol. Online J. 5:7.
7. Brown, A. E., L. Markowitz, S. Nitayaphan, P. Morgan, S. Sukwit, S. Chinaworapong, S. Leelasupasri, and D. Birx. 2000. DTH responsiveness of HIV-infected Thai adults. J. Med. Assoc. Thai. 83:633-639.
8. Burrows, S. R., J. Gardner, R. Khanna, T. Steward, D. J. Moss, S. Rodda, and A. Suhrbier. 1994. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J. Gen. Virol. 75:2489-2493.
9. Burrows, S. R., S. J. Rodda, A. Suhrbier, H. M. Geysen, and D. J. Moss. 1992. The specificity of recognition of a cytotoxic T lymphocyte epitope. Eur. J. Immunol. 22:191-195.
10. Burrows, S. R., T. B. Sculley, I. S. Misko, C. Schmidt, and D. J. Moss. 1990. An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3). J. Exp. Med. 171:345-349.
11. Burrows, S. R., S. L. Silins, S. M. Cross, C. A. Peh, M. Rischmueller, J. M. Burrows, S. L. Elliott, and J. McCluskey. 1997. Human leukocyte antigen phenotype imposes complex constraints on the antigen-specific cytotoxic T lymphocyte repertoire. Eur. J. Immunol. 27:178-182.
12. Burrows, S. R., S. L. Silins, D. J. Moss, R. Khanna, I. S. Misko, and V. P. Argaet. 1995. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J. Exp. Med. 182:1703-1715.
13. Callan, M. F., N. Steven, P. Krausa, J. D. Wilson, P. A. Moss, G. M. Gillespie, J. I. Bell, A. B. Rickinson, and A. J. McMichael. 1996. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat. Med. 2:906-911.
14. Callan, M. F., L. Tan, N. Annels, G. S. Ogg, J. D. Wilson, C. A. O'Callaghan, N. Steven, A. J. McMichael, and A. B. Rickinson. 1998. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187:1395-1402.
15. Candy, B., and M. Hotopf. 2006. Steroids for symptom control in infectious mononucleosis. Cochrane Database Syst. Rev. 3:CD004402.
16. Catalina, M. D., J. L. Sullivan, R. M. Brody, and K. Luzuriaga. 2002. Phenotypic and functional heterogeneity of EBV epitope-specific CD8+ T cells. J. Immunol. 168:4184-4191.
17. Chen, W., and J. McCluskey. 2006. Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv. Cancer Res. 95:203-247.
18. Chetham, M. M., and K. B. Roberts. 1991. Infectious mononucleosis in adolescents. Pediatr. Ann. 20:206-213.
19. Crawford, D. H., K. F. Macsween, C. D. Higgins, R. Thomas, K. McAulay, H. Williams, N. Harrison, S. Reid, M. Conacher, J. Douglas, and A. J. Swerdlow. 2006. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin. Infect. Dis. 43:276-282.
20. Elliott, S. L., S. Pye, T. Le, L. Mateo, J. Cox, L. Macdonald, A. A. Scalzo, C. A. Forbes, and A. Suhrbier. 1999. Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems. Vaccine 17:2009-2019.
21. + T-cell epitopes. J. Virol. 80:4717-4728.
22. Haring, J. S., V. P. Badovinac, and J. T. Harty. 2006. Inflaming the CD8+ T cell response. Immunity 25:19-29.
23. Hersey, P., S. W. Menzies, B. Coventry, T. Nguyen, M. Farrelly, S. Collins, D. Hirst, and H. Johnson. 2005. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol. Immunother. 54:208-218.
24. Hislop, A. D., N. E. Annels, N. H. Gudgeon, A. M. Leese, and A. B. Rickinson. 2002. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J. Exp. Med. 195:893-905.
25. Hislop, A. D., N. H. Gudgeon, M. F. Callan, C. Fazou, H. Hasegawa, M. Salmon, and A. B. Rickinson. 2001. EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J. Immunol. 167:2019-2029.
26. Hjalgrim, H., K. E. Smedby, K. Rostgaard, D. Molin, S. Hamilton-Dutoit, E. T. Chang, E. Ralfkiaer, C. Sundstrom, H. O. Adami, B. Glimelius, and M. Melbye. 2007. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res. 67:2382-2388.
27. Jacobs, R. L., R. S. Lowe, and B. Q. Lanier. 1982. Adverse reactions to tetanus toxoid. JAMA 247:40-42.
28. Kerr, B. M., N. Kienzle, J. M. Burrows, S. Cross, S. L. Silins, M. Buck, E. M. Benson, B. Coupar, D. J. Moss, and T. B. Sculley. 1996. Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus. J. Virol. 70:8858-8864.
29. Khanna, R., S. Bell, M. Sherritt, A. Galbraith, S. R. Burrows, L. Rafter, B. Clarke, R. Slaughter, M. C. Falk, J. Douglass, T. Williams, S. L. Elliott, and D. J. Moss. 1999. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl. Acad. Sci. USA 96:10391-10396.
30. Khanna, R., S. R. Burrows, J. Nicholls, and L. M. Poulsen. 1998. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur. J. Immunol. 28:451-458.
31. Khanna, R., S. R. Burrows, A. Suhrbier, C. A. Jacob, H. Griffin, I. S. Misko, T. B. Sculley, M. Rowe, A. B. Rickinson, and D. J. Moss. 1993. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2. J. Immunol. 150:5154-5162.
32. Klatt, T., Q. Ouyang, T. Flad, I. Koetter, H. J. Buhring, H. Kalbacher, G. Pawelec, and C. A. Muller. 2005. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis. J. Rheumatol. 32:239-251.
33. Kuhlwein, A., and A. Bleyl. 1985. Tetanus antitoxin levels and reactions following tetanus vaccination. Hautarzt 36:462-464.
34. Lee, S. P., W. A. Thomas, R. J. Murray, F. Khanim, S. Kaur, L. S. Young, M. Rowe, M. Kurilla, and A. B. Rickinson. 1993. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J. Virol. 67:7428-7435.
35. Lin, C. L., W. F. Lo, T. H. Lee, Y. Ren, S. L. Hwang, Y. F. Cheng, C. L. Chen, Y. S. Chang, S. P. Lee, A. B. Rickinson, and P. K. Tam. 2002. Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 62:6952-6958.
36. Lopez, J. A., C. Weilenman, R. Audran, M. A. Roggero, A. Bonelo, J. M. Tiercy, F. Spertini, and G. Corradin. 2001. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. J. Immunol. 31:1989-1998.
37. Moss, D. J., S. R. Burrows, D. J. Castelino, R. G. Kane, J. H. Pope, A. B. Rickinson, M. P. Alpers, and P. F. Heywood. 1983. A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea. Int. J. Cancer 31:727-732.
38. Moss, D. J., C. Schmidt, S. Elliott, A. Suhrbier, S. Burrows, and R. Khanna. 1996. Strategies involved in developing an effective vaccine for EBV-associated diseases. Adv. Cancer Res. 69:213-245.
39. Moss, D. J., A. Suhrbier, and S. L. Elliott. 1998. Candidate vaccines for Epstein-Barr virus. BMJ 317:423-424.
40. Moutschen, M., P. Leonard, E. M. Sokal, F. Smets, M. Haumont, P. Mazzu, A. Bollen, F. Denamur, P. Peeters, G. Dubin, and M. Denis. 2007. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 25:4697-4705.
41. Nielsen, T. R., K. Rostgaard, N. M. Nielsen, N. Koch-Henriksen, S. Haahr, P. S. Sorensen, and H. Hjalgrim. 2007. Multiple sclerosis after infectious mononucleosis. Arch. Neurol. 64:72-75.
42. Parra-Lopez, C., J. M. Calvo-Calle, T. O. Cameron, L. E. Vargas, L. M. Salazar, M. E. Patarroyo, E. Nardin, and L. J. Stern. 2006. Major histocompatibility complex and T cell interactions of a universal T cell epitope from Plasmodium falciparum circumsporozoite protein. J. Biol. Chem. 281:14907-14917.
43. Pope, J. H. 1968. Establishment of cell lines from Australian leukaemic patients: presence of a herpes-like virus. Aust. J. Exp. Biol. Med. Sci. 46:643-645.
44. Rickinson, A. B., and D. J. Moss. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15:405-431.
45. Sauce, D., M. Larsen, S. J. Curnow, A. M. Leese, P. A. Moss, A. D. Hislop, M. Salmon, and A. B. Rickinson. 2006. EBV-associated mononucleosis leads to long-term global deficit in T-cell responsiveness to IL-15. Blood 108:11-18.
46. Saul, A., G. Lawrence, A. Smillie, C. M. Rzepczyk, C. Reed, D. Taylor, K. Anderson, A. Stowers, R. Kemp, A. Allworth, R. F. Anders, G. V. Brown, D. Pye, P. Schoofs, D. O. Irving, S. L. Dyer, G. C. Woodrow, W. R. Briggs, R. Reber, and D. Sturchler. 1999. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 17:3145-3159.
47. Savoldo, B., J. A. Goss, M. M. Hammer, L. Zhang, T. Lopez, A. P. Gee, Y. F. Lin, R. E. Quiros-Tejeira, P. Reinke, S. Schubert, S. Gottschalk, M. J. Finegold, M. K. Brenner, C. M. Rooney, and H. E. Heslop. 2006. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108:2942-2949.
48. Scalzo, A. A., S. L. Elliott, J. Cox, J. Gardner, D. J. Moss, and A. Suhrbier. 1995. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J. Virol. 69:1306-1309.
49. Sherritt, M. A., M. Bharadwaj, J. M. Burrows, L. E. Morrison, S. L. Elliott, J. E. Davis, L. M. Kear, R. E. Slaughter, S. C. Bell, A. J. Galbraith, R. Khanna, and D. J. Moss. 2003. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 75:1556-1560.
50. Sherritt, M. A., J. Gardner, S. L. Elliott, C. Schmidt, D. Purdie, G. Deliyannis, W. R. Heath, and A. Suhrbier. 2000. Effect of pre-existing cytotoxic T lymphocytes on therapeutic vaccines. Eur. J. Immunol. 30:671-677.
51. Silins, S. L., S. M. Cross, S. L. Elliott, S. J. Pye, J. M. Burrows, D. J. Moss, and I. S. Misko. 1997. Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection. Int. Immunol. 9:1745-1755.
52. Silins, S. L., S. M. Cross, S. L. Elliott, S. J. Pye, S. R. Burrows, J. M. Burrows, D. J. Moss, V. P. Argaet, and I. S. Misko. 1996. Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis. J. Exp. Med. 184:1815-1824.
53. Silins, S. L., M. A. Sherritt, J. M. Silleri, S. M. Cross, S. L. Elliott, M. Bharadwaj, T. T. Le, L. E. Morrison, R. Khanna, D. J. Moss, A. Suhrbier, and I. S. Misko. 2001. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood 98:3739-3744.
54. Suhrbier, A. 1997. Multi-epitope DNA vaccines. Immunol. Cell Biol. 75:402-408.
55. Suhrbier, A. 2002. Polytope vaccines for the codelivery of multiple CD8 T-cell epitopes. Expert Rev. Vaccines 1:207-213.
56. Svedmyr, E., I. Ernberg, J. Seeley, O. Weiland, G. Masucci, K. Tsukuda, R. Szigeti, M. G. Masucci, H. Blomogren, and W. Berthold. 1984. Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis. Clin. Immunol. Immunopathol. 30:437-450.
57. Takeuchi, K., K. Tanaka-Taya, Y. Kazuyama, Y. M. Ito, S. Hashimoto, M. Fukayama, and S. Mori. 2006. Prevalence of Epstein-Barr virus in Japan: trends and future prediction. Pathol. Int. 56:112-116.
58. Tan, L. C., N. Gudgeon, N. E. Annels, P. Hansasuta, C. A. O'Callaghan, S. Rowland-Jones, A. J. McMichael, A. B. Rickinson, and M. F. Callan. 1999. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J. Immunol. 162:1827-1835.
59. Tattevin, P., Y. Le Tulzo, S. Minjolle, A. Person, J. M. Chapplain, C. Arvieux, R. Thomas, and C. Michelet. 2006. Increasing incidence of severe Epstein-Barr virus-related infectious mononucleosis: surveillance study. J. Clin. Microbiol. 44:1873-1874.
60. Thomson, S. A., R. Khanna, J. Gardner, S. R. Burrows, B. Coupar, D. J. Moss, and A. Suhrbier. 1995. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc. Natl. Acad. Sci. USA 92:5845-5849.
61. Toes, R. E., R. Offringa, R. J. Blom, C. J. Melief, and W. M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93:7855-7860.
62. Toledo, H., A. Baly, O. Castro, S. Resik, J. Laferte, F. Rolo, L. Navea, L. Lobaina, O. Cruz, J. Miguez, T. Serrano, B. Sierra, L. Perez, M. E. Ricardo, M. Dubed, A. L. Lubian, M. Blanco, J. C. Millau, A. Ortega, E. Iglesias, E. Penton, Z. Martin, J. Perez, M. Diaz, and C. A. Duarte. 2001. A phase I clinical trial of a multiepitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 19:4328-4336.
63. Wills, M. R., A. J. Carmichael, M. P. Weekes, K. Mynard, G. Okecha, R. Hicks, and J. G. Sissons. 1999. Human virus-specific CD8+ CTL clones revert from CD45ROhigh to CD45RAhigh in vivo: CD45RAhighCD8+ T cells comprise both naive and memory cells. J. Immunol. 162:7080-7087.